Sanofi SA backed out of its $750 million effort to advance Maze Therapeutics Inc.’s oral Pompe disease candidate, MZE-001, after the U.S. FTC filed a federal lawsuit to block the deal, claiming the ...
Astellas’ gene therapy ambitions have faced yet another setback. The FDA has slammed the brakes on a phase 1/2 study of the Japanese pharma’s Pompe disease med while the regulator investigates a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback